Peptide-MHC Interaction Prediction for Accurate Neoantigen Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately identify neoantigens that effectively provoke a robust immune response for personalized cancer vaccines due to the inability to predict peptide-MHC interactions and immunogenicity, leading to false positives and ineffective vaccine candidates.
Innovation Solution
A machine-learning model processes peptide and MHC data using transformer stages and protein language models to generate composite representations, predicting interactions, binding affinities, and immunogenicity, thereby selecting optimal neoantigen candidates for personalized cancer vaccines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current prediction methods are used to identify neoantigens, then the process is simpler and faster, but the accuracy is low leading to false positives and ineffective vaccine candidates
Solution Approach 1:
The patent combines multiple prediction methods (MHC binding affinity prediction, peptide stability prediction, and immunogenicity prediction) into a single integrated machine learning system. This merging of multiple functions into one unified model resolves the contradiction by achieving high accuracy through comprehensive analysis while managing complexity through integrated architecture rather than separate sequential tools.
Solution Approach 2:
The prediction system uses composite features combining multiple types of data (amino acid sequences, MHC allele information, binding affinity metrics, stability scores) to create a multifaceted prediction model. This composite approach enables accurate neoantigen identification by considering multiple factors simultaneously, resolving the accuracy-complexity contradiction through sophisticated feature integration.
2Reliability
If multiple prediction criteria are applied to select neoantigen candidates, then the accuracy of vaccine candidate selection improves, but the time and computational resources required increase
Solution Approach 1:
The machine learning model is pre-trained on extensive datasets containing known MHC binding affinities and immunogenicity outcomes. This preliminary training enables the system to rapidly evaluate new neoantigen candidates using pre-learned patterns, resolving the contradiction by performing the computationally intensive learning work beforehand rather than during actual candidate screening.
Solution Approach 2:
The patent replaces traditional mechanical experimental screening methods with computational machine learning predictions. By substituting wet-lab experiments with in-silico predictions, the system achieves reliable candidate selection through computational algorithms that process multiple criteria simultaneously, dramatically reducing time while maintaining or improving reliability.
Data Source
AI summary
This present disclosure relates to immunology, particularly methods of predicting whether a therapeutic protein is likely to trigger an immunogenic response. An example method for predicting an amino acid-immunoprotein complex (IPC) interaction may comprise: accessing a set of amino acid sequences; accessing an immunoprotein complex (IPC) sequence identified for an IPC of a subject; processing a set of amino acid sequence representations to generate a set of transformed amino acid sequence representations based on a set of element-focused scores representing binding cores of the set of amino acid sequence representations; processing an IPC sequence representation to generate a transformed IPC sequence representation; generating composite representations; and determining one or more predicted amino acid-IPC interactions based on the composite representations.